Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
2.78
USD
|
+2.21%
|
|
+1.09%
|
+54.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7.521
|
233.5
|
63.09
|
31.37
|
43.56
|
107
|
-
|
-
|
Enterprise Value (EV)
1 |
7.521
|
233.5
|
63.09
|
31.37
|
43.56
|
107
|
107
|
107
|
P/E ratio
|
-0.43
x
|
-0.98
x
|
-1.89
x
|
-0.37
x
|
-1.1
x
|
-2.16
x
|
-4.46
x
|
-3.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
3.21
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
3.21
x
|
-
|
EV / EBITDA
|
-584,522
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-542,761
x
|
-15,347,759
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
0.79
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
720
|
15,160
|
14,307
|
13,757
|
24,198
|
38,507
|
-
|
-
|
Reference price
2 |
10.44
|
15.40
|
4.410
|
2.280
|
1.800
|
2.780
|
2.780
|
2.780
|
Announcement Date
|
3/17/20
|
3/30/21
|
3/24/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
33.33
|
-
|
EBITDA
|
-12.87
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.18
|
-18.46
|
-36.87
|
-88.43
|
-43
|
-43.9
|
-13.93
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-41.8%
|
-
|
Earnings before Tax (EBT)
1 |
-16.01
|
-23.22
|
-36.86
|
-87.97
|
-40.33
|
-43.3
|
-13.33
|
-
|
Net income
1 |
-16.01
|
-22.81
|
-34.51
|
-87.97
|
-40.33
|
-43.3
|
-33.56
|
-70.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-100.67%
|
-
|
EPS
2 |
-24.48
|
-15.72
|
-2.330
|
-6.160
|
-1.640
|
-1.287
|
-0.6233
|
-0.7300
|
Free Cash Flow
|
-13.86
|
-15.21
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/20
|
3/30/21
|
3/24/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.385
|
-9.859
|
-9.283
|
-10.6
|
-58.69
|
-11.11
|
-10.35
|
-11.2
|
-10.34
|
-10.87
|
-10.9
|
-11
|
-11.1
|
-16.5
|
-19.55
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.385
|
-9.864
|
-9.247
|
-10.47
|
-58.38
|
-10.77
|
-9.579
|
-10.35
|
-9.626
|
-10.3
|
-10.9
|
-11
|
-11.1
|
-16.2
|
-19.25
|
Net income
1 |
-8.806
|
-9.864
|
-9.247
|
-10.47
|
-58.38
|
-10.77
|
-9.579
|
-10.35
|
-9.626
|
-10.3
|
-10.9
|
-11
|
-11.1
|
-16.2
|
-19.25
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.6900
|
-0.6500
|
-0.7300
|
-4.090
|
-0.7500
|
-0.4000
|
-0.3500
|
-0.2900
|
-0.3400
|
-0.3233
|
-0.3167
|
-0.3233
|
-0.3700
|
-0.4400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/12/22
|
8/11/22
|
11/14/22
|
3/30/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/28/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-13.9
|
-15.2
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
13.10
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/20
|
3/30/21
|
3/24/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
2.78
USD Average target price
14
USD Spread / Average Target +403.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +54.44% | 107M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +3.23% | 22.78B | | -10.44% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|